{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:53:20Z","timestamp":1791010400782,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In Japan, high-dose corticosteroids serve as the first-line treatment for Vogt\u2013Koyanagi\u2013Harada disease (VKHD), whereas cyclosporine (CysA) and adalimumab are reserved for recurrent cases. However, some patients require prolonged corticosteroid therapy despite these immunosuppressants. Our institution generally utilizes CysA as the first-line steroid-sparing immunosuppressive agent and low-dose methotrexate (MTX; 6\u20138 mg\/week) as a second-line or alternative therapy. We evaluated recurrence rates and treatment-related adverse effects, focusing on MTX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Retrospective observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed 64 patients with first-onset VKHD treated with systemic corticosteroids (high-dose intravenous pulse therapy followed by oral prednisolone [PSL]) between April 2017 and April 2024. Recurrence was defined as the reappearance of intraocular inflammation after initial control. Clinical data regarding recurrence patterns and subsequent treatments, including MTX and CysA, were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort comprised 28 men and 36 women (mean age, 52.3 \u00b1 15.4 years). Twenty-two of 64 patients (34%) experienced recurrence. Among these, 15 patients received CysA; 8 required switching to MTX because of insufficient disease control, difficulty tapering corticosteroids, or CysA-related adverse effects. After initiating MTX, six of eight patients discontinued PSL after a median of 17.5 months and remained recurrence-free during a median of 10 months. In contrast, among seven patients treated with CysA alone, five discontinued PSL after 34 months and remained recurrence-free for 24 months. No severe MTX-related adverse effects were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low-dose MTX was well tolerated and enabled discontinuation of corticosteroids in patients with recurrent VKHD, supporting its utility as a feasible steroid-sparing therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-026-01432-2","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:25:34Z","timestamp":1791008734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral methotrexate as a steroid-sparing therapy after high-dose intravenous corticosteroid pulse therapy for refractory Vogt\u2013Koyanagi\u2013Harada disease"],"prefix":"10.1007","author":[{"given":"Satoko","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6283-5466","authenticated-orcid":false,"given":"Kazuichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Shunto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"1432_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10384-020-00809-1","volume":"65","author":"K Sonoda","year":"2021","unstructured":"Sonoda K, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H, et al. Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65:184\u201390.","journal-title":"Jpn J Ophthalmol"},{"issue":"33","key":"1432_CR2","first-page":"66","volume":"15","author":"YR Hsu","year":"2018","unstructured":"Hsu YR, Huang JC, Tao Y, Kaburaki T, Lee CS, Lin TC, et al. Noninfectious uveitis in the Asia-Pacific region. Eye (Lond). 2018;15(33):66\u201377.","journal-title":"Eye (Lond)"},{"key":"1432_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","volume":"131","author":"RW Read","year":"2001","unstructured":"Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647\u201352.","journal-title":"Am J Ophthalmol"},{"key":"1432_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0039-6257(05)80105-5","volume":"39","author":"RS Moorthy","year":"1995","unstructured":"Moorthy RS, Inomata H, Rao NA. Vogt\u2013Koyanagi\u2013Harada syndrome. Surv Ophthalmol. 1995;39:265\u201392.","journal-title":"Surv Ophthalmol"},{"key":"1432_CR5","first-page":"1053","volume":"38","author":"S Kotake","year":"1984","unstructured":"Kotake S, Ohno S. Pulse methyl prednisolone therapy in the treatment of Vogt-Koyanagi-Harada disease. Rinsho Ganka. 1984;38:1053\u20138 ((in Japanese)).","journal-title":"Rinsho Ganka"},{"key":"1432_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10384-015-0377-1","volume":"59","author":"C Iwahashi","year":"2015","unstructured":"Iwahashi C, Okuno K, Hashida N, Nakai K, Ohguro N, Nishida K. Incidence and clinical features of recurrent Vogt\u2013Koyanagi\u2013Harada disease in Japanese individuals. Jpn J Ophthalmol. 2015;59:157\u201363.","journal-title":"Jpn J Ophthalmol"},{"key":"1432_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/bjophthalmol-2017-311691","volume":"103","author":"M Nakayama","year":"2019","unstructured":"Nakayama M, Keino H, Watanabe T, Okada AA. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids. Br J Ophthalmol. 2019;103:274\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1432_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09273940500536766","volume":"14","author":"I Paredes","year":"2006","unstructured":"Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt\u2013Koyanagi\u2013Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87\u201390.","journal-title":"Ocul Immunol Inflamm"},{"key":"1432_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-021-00878-w","author":"T Ono","year":"2022","unstructured":"Ono T, Goto H, Sakai T, Nitta F, Mizuki N, Takase H, et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 2022. https:\/\/doi.org\/10.1007\/s10384-021-00878-w.","journal-title":"Jpn J Ophthalmol"},{"key":"1432_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/09273948.2022.2037657","volume":"31","author":"M Shinagawa","year":"2023","unstructured":"Shinagawa M, Namba K, Mizuuchi K, Iwata D, Hase K, Suzuki K, et al. The steroid-sparing effect of adalimumab in the treatment for the recurrent phase of Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2023;31:501\u20135.","journal-title":"Ocul Immunol Inflamm"},{"key":"1432_CR11","first-page":"104","volume":"31","author":"M Takeuchi","year":"2023","unstructured":"Takeuchi M, Kezuka T, Sugita S, Namba K, Suzuki K, Harada Y, et al. Adalimumab treatment for chronic recurrent Vogt\u2013Koyanagi\u2013Harada disease with sunset glow fundus. Ocul Immunol Inflamm. 2023;31:104\u201311.","journal-title":"Ocul Immunol Inflamm"},{"key":"1432_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10384-025-01213-3","volume":"69","author":"K Tsubota","year":"2025","unstructured":"Tsubota K, Goto H, Asakage M, Kinoshita Y, Nonaka R, Wakatsuki K, et al. Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 2025;69:805\u201312.","journal-title":"Jpn J Ophthalmol"},{"key":"1432_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s10384-021-00897-7","volume":"66","author":"K Namba","year":"2022","unstructured":"Namba K, Takase H, Usui Y, Nitta F, Maruyama K, Kusuhara S, et al. Multicenter, retrospective, observational study for the treatment pattern of systemic corticosteroids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis. Jpn J Ophthalmol. 2022;66:130\u201341.","journal-title":"Jpn J Ophthalmol"},{"key":"1432_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s10384-011-0092-5","volume":"56","author":"Y Kondo","year":"2012","unstructured":"Kondo Y, Fukuda K, Suzuki K, Nishida T. Chronic noninfectious uveitis associated with Vogt-Koyanagi-Harada disease treated with low-dose weekly systemic methotrexate. Jpn J Ophthalmol. 2012;56:104\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"1432_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ajo.2021.03.036","volume":"228","author":"The Standardization of uveitis nomenclature (SUN) Working Group","year":"2021","unstructured":"The Standardization of uveitis nomenclature (SUN) Working Group. Classification criteria for Vogt\u2013Koyanagi\u2013Harada disease. Am J Ophthalmol. 2021;228:205\u201311.","journal-title":"Am J Ophthalmol"},{"key":"1432_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.oret.2017.07.016","volume":"2","author":"K Maruyama","year":"2018","unstructured":"Maruyama K, Noguchi A, Shimizu A, Mao Z, Wang Z, Shiraki N, et al. Predictors of recurrence in Vogt\u2013Koyanagi\u2013Harada disease. Ophthalmol Retina. 2018;2:343\u201350.","journal-title":"Ophthalmol Retina"},{"key":"1432_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133632","volume":"11","author":"M Accorinti","year":"2022","unstructured":"Accorinti M, Saturno MC, Iannetti L, Manni P, Mastromarino D, Pirraglia MP. Treatment and prognosis of Vogt-Koyanagi-Harada disease: real-life experience in long-term follow-up. J Clin Med. 2022;11:3632.","journal-title":"J Clin Med"},{"key":"1432_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ophtha.2006.07.040","volume":"114","author":"P Yang","year":"2007","unstructured":"Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606\u201314.","journal-title":"Ophthalmology"},{"key":"1432_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajo.2020.07.036","volume":"220","author":"O Ei Lin","year":"2020","unstructured":"Ei Lin O, Chee SP, Wong KKY, Myint HH. Vogt-Koyanagi-Harada disease managed with immunomodulatory therapy within 3 months of disease onset. Am J Ophthalmol. 2020;220:37\u201344.","journal-title":"Am J Ophthalmol"},{"key":"1432_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ajo.2016.06.004","volume":"168","author":"E Shen","year":"2016","unstructured":"Shen E, Rathinam SR, Babu M, Kanakath A, Thundikandy R, Lee SM, et al. Outcomes of Vogt-Koyanagi-Harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies. Am J Ophthalmol. 2016;168:279\u201386.","journal-title":"Am J Ophthalmol"},{"key":"1432_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ajo.2024.06.004","volume":"267","author":"NR Acharya","year":"2024","unstructured":"Acharya NR, Rathinam SR, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, et al. Outcomes in patients with Vogt-Koyanagi-Harada disease from the first-line antimetabolites for steroid-sparing treatment uveitis trial. Am J Ophthalmol. 2024;267:100\u201311.","journal-title":"Am J Ophthalmol"},{"key":"1432_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00417-011-1910-7","volume":"250","author":"K Nakai","year":"2012","unstructured":"Nakai K, Gomi F, Ikuno Y, Yasuno Y, Nouchi T, Ohguro N, et al. Choroidal observations in Vogt\u2013Koyanagi\u2013Harada disease using high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol. 2012;250:1089\u201395.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1432_CR23","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1080\/09273948.2024.2337836","volume":"32","author":"A Tanikawa","year":"2024","unstructured":"Tanikawa A, Maruyama K, Liu S, Mao Z, Wang Z, Shiraki N, et al. Unveiling key pathological indicators for disease progression in Vogt Koyanagi Harada disease and sympathetic ophthalmia through advanced choroidal volume analysis. Ocul Immunol Inflamm. 2024;32:2170\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"1432_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/bjophthalmol-2014-306439","volume":"100","author":"Y Tagawa","year":"2016","unstructured":"Tagawa Y, Namba K, Mizuuchi K, Takemoto Y, Iwata D, Uno T, et al. Choroidal thickening prior to anterior recurrence in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2016;100:473\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1432_CR25","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1097\/01.ASN.0000034945.61533.26","volume":"13","author":"C IsnardBagnis","year":"2002","unstructured":"IsnardBagnis C, Tezenas du Montcel S, Beaufils H, Jouanneau C, Jaudon MC, Maksud P, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002;13:2962\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1432_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Br\u00e9zin AP, Chee SP, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology. 2018;125:757\u201373.","journal-title":"Ophthalmology"},{"key":"1432_CR27","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","volume":"44","author":"AE van Ede","year":"2001","unstructured":"van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44:1515\u201324.","journal-title":"Arthritis Rheum"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01432-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:25:35Z","timestamp":1791008735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01432-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":27,"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01432-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Fujimoto, None; K. Maruyama, None; T. Shunto, None; K. Nishida, None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}